Literature DB >> 8522688

Analysis of beta-adrenergic receptor mRNA levels in human ventricular biopsy specimens by quantitative polymerase chain reactions: progressive reduction of beta 1-adrenergic receptor mRNA in heart failure.

S Engelhardt1, M Böhm, E Erdmann, M J Lohse.   

Abstract

OBJECTIVES: This study investigated the relation between the severity of heart failure and the extent of the reduction of beta 1-adrenergic receptor messenger ribonucleic acid (mRNA) levels in biopsy specimens from the ventricular septum obtained during cardiac catheterization of patients with various degrees of heart failure.
BACKGROUND: Heart failure is accompanied by desensitization of the beta-adrenergic receptor system, which is in part due to downregulation of beta 1-adrenergic receptors. Downregulation of beta 1-adrenergic receptors has been suggested to be caused by reductions in mRNA levels.
METHODS: Because biopsy specimens were small and receptor mRNAs not abundant, mRNA levels were determined by quantitative reverse transcription/polymerase chain reactions. This method was validated by measuring synthetic ribonucleic acid (RNA) standards and samples from explanted hearts by solution hybridization assays. Both methods yielded similar results, but the polymerase chain reaction method was approximately 1,000-fold more sensitive. Sources of variations in the polymerase chain reaction were quantitated and found to be best controlled for by determination of the glyceraldehyde phosphate dehydrogenase mRNA as an endogenous control.
RESULTS: Beta 1-adrenergic receptor mRNA levels in the biopsy specimens were decreased by 7% in mild (New York Heart Association functional class II), 26% in moderate (functional class III) and > 50% in severe heart failure (functional class IV). There was a good correlation between hemodynamic indicators of heart failure and beta 1-adrenergic receptor mRNA levels. In contrast, beta 2-adrenergic receptor mRNA levels were apparently unaffected by heart failure.
CONCLUSIONS: Reduced beta 1-adrenergic receptor mRNA levels occur early in heart failure and can be detected in septal biopsy specimens during right heart catheterization. The reduction in beta 1-adrenergic receptor expression may contribute to further loss of cardiac function.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8522688     DOI: 10.1016/0735-1097(95)00425-4

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  26 in total

1.  Chronic sympathetic activation promotes downregulation of β-adrenoceptor-mediated effects in the guinea pig heart independently of structural remodeling and systolic dysfunction.

Authors:  Ewa Soltysinska; Stefanie Thiele; Søren Peter Olesen; Oleg E Osadchii
Journal:  Pflugers Arch       Date:  2011-08-03       Impact factor: 3.657

2.  The deubiquitinase ubiquitin-specific protease 20 is a positive modulator of myocardial β1-adrenergic receptor expression and signaling.

Authors:  Samuel Mon-Wei Yu; Pierre-Yves Jean-Charles; Dennis M Abraham; Suneet Kaur; Clarice Gareri; Lan Mao; Howard A Rockman; Sudha K Shenoy
Journal:  J Biol Chem       Date:  2018-12-11       Impact factor: 5.157

3.  Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice.

Authors:  S Engelhardt; L Hein; F Wiesmann; M J Lohse
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

Review 4.  Modification of beta-adrenoceptor signal transduction pathway by genetic manipulation and heart failure.

Authors:  X Wang; N S Dhalla
Journal:  Mol Cell Biochem       Date:  2000-11       Impact factor: 3.396

Review 5.  Modulation of beta-adrenergic receptor signaling in heart failure and longevity: targeting adenylyl cyclase type 5.

Authors:  David Ho; Lin Yan; Kousaku Iwatsubo; Dorothy E Vatner; Stephen F Vatner
Journal:  Heart Fail Rev       Date:  2010-09       Impact factor: 4.214

Review 6.  Left ventricular assist device unloading effects on myocardial structure and function: current status of the field and call for action.

Authors:  Stavros G Drakos; Abdallah G Kfoury; Craig H Selzman; Divya Ratan Verma; John N Nanas; Dean Y Li; Josef Stehlik
Journal:  Curr Opin Cardiol       Date:  2011-05       Impact factor: 2.161

7.  Changes in gene expression in the intact human heart. Downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium.

Authors:  B D Lowes; W Minobe; W T Abraham; M N Rizeq; T J Bohlmeyer; R A Quaife; R L Roden; D L Dutcher; A D Robertson; N F Voelkel; D B Badesch; B M Groves; E M Gilbert; M R Bristow
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

Review 8.  β₂ AR agonists in treatment of chronic heart failure: long path to translation.

Authors:  Mark I Talan; Ismayil Ahmet; Riu-Ping Xiao; Edward G Lakatta
Journal:  J Mol Cell Cardiol       Date:  2010-10-01       Impact factor: 5.000

9.  Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised β-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy.

Authors:  Haodi Wu; Jaecheol Lee; Ludovic G Vincent; Qingtong Wang; Mingxia Gu; Feng Lan; Jared M Churko; Karim I Sallam; Elena Matsa; Arun Sharma; Joseph D Gold; Adam J Engler; Yang K Xiang; Donald M Bers; Joseph C Wu
Journal:  Cell Stem Cell       Date:  2015-06-18       Impact factor: 24.633

Review 10.  Chronic heart failure: beta-blockers and pharmacogenetics.

Authors:  Junichi Azuma; Shinpei Nonen
Journal:  Eur J Clin Pharmacol       Date:  2008-10-07       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.